Vivo Capital, LLC
Q4 2025 13F-HR Holdings
Net value change ($000)
+304,359
(24.5%)
New positions
7
Sold out positions
7
Turnover %
20.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| TERN | 164,229 | 317.1% |
| PRAX | 86,398 | 819.6% |
| CDTX | 85,737 | 68.3% |
| COGT | 45,160 | 112.8% |
| DBVT | 36,644 | 347.5% |
| SABS | 19,757 | 86.1% |
| ANRO | 18,433 | NEW |
| DYN | 18,070 | 54.6% |
| ABVX | 17,949 | 58.8% |
| CMPX | 17,850 | 53.4% |
Top Reduces (Value $000, Stocks/ETFs)
| VRNA | -148,693 | -100.0% |
| SLNO | -112,573 | -73.1% |
| TRML | -28,310 | -100.0% |
| AKRO | -20,639 | -100.0% |
| ORIC | -20,191 | -53.8% |
| RZLT | -19,857 | -100.0% |
| VSTM | -14,813 | -63.4% |
| Astria Therapeutics, Inc. | -11,304 | -100.0% |
| DCTH | -6,122 | -100.0% |
| 89bio, Inc. | -5,539 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|